Preclinical pharmacology of sertraline: a potent and specific inhibitor of serotonin reuptake.
Specific serotonin reuptake inhibitors constitute a new class of psychotherapeutic agents that promote enhanced central serotonergic neurotransmission in animal studies. Sertraline, a member of this class, exhibits considerable potency and specificity in inhibiting serotonin neuronal reuptake in preclinical studies. Thus, it is likely to exert antidepressant activity without significant anticholinergic, cardiovascular, and sedative side effects. Other animal studies demonstrating decreases in food intake and body weight and reduction in voluntary alcohol consumption after sertraline administration suggest a potential for wider clinical application.
Koe
B K
BK
Department of Neuroscience, Pfizer Inc., Groton, Conn. 06340.
D015057:1-Naphthylamine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D015536:Down-Regulation / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D006801:Humans; D066298:In Vitro Techniques; D011903:Raphe Nuclei / Q000187:drug effects / Q000502:physiology; D051381:Rats; D011985:Receptors, Serotonin / Q000187:drug effects / Q000502:physiology; D012701:Serotonin / Q000378:metabolism / Q000502:physiology; D012702:Serotonin Antagonists / Q000494:pharmacology*; D020280:Sertraline; D009435:Synaptic Transmission / Q000187:drug effects; D013574:Synaptosomes / Q000187:drug effects / Q000378:metabolism
D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D012701:Serotonin; D015057:1-Naphthylamine; D020280:Sertraline